Oct 12, 2006 by Brian LawlerThe Man Who Deflated InflationAs inflation rises, unemployment falls, right? The newest Nobel laureate proved otherwise.
Oct 12, 2006 by Brian LawlerGenzyme Runs a Tight ShipRevenues are up at the biopharmaceutical company, but shares dropped in morning trading.
Oct 11, 2006 by Brian LawlerWaiting on NorthfieldThe development-stage drug company waits for clinical trial results.
Oct 11, 2006 by Brian LawlerMonopoly Woes Help Chattem GrowAcquisitions boost Chattem shares to new highs.
Oct 11, 2006 by Brian LawlerEverything Is All Right at GenentechGenentech shares aren't cheap, but the company has a strong history and solid management.
Oct 9, 2006 by Brian LawlerNew Drug for New RiverAn approvable letter from the FDA sends shares of New River Pharmaceuticals up.
Oct 9, 2006 by Brian LawlerThe Commandments of Biotech Investing, Part 2It's a complex field, but it's not impossible to master. Here are some further tips.
Oct 9, 2006 by Brian LawlerMuch-Needed Publicity for MillenniumA cancer-fighting drug is set to gain exposure for a new treatment.
Oct 6, 2006 by Brian LawlerNo Bloodbath at ImmucorThe company appears right on track for double-digit revenue growth.
Oct 6, 2006 by Brian LawlerWyeth Makes Investors HappyIt's facing some challenges, but there's a lot to like about this drug company.
Oct 5, 2006 by Brian LawlerElan Extends Tysabri's ReachThe MS-fighting drug gains approval in Canada.
Oct 4, 2006 by Brian LawlerUnwelcome Guests at ImCloneImClone's board of directors votes against Carl Icahn's proposed removal of six company directors.
Oct 3, 2006 by Brian LawlerLCA-Vision's Blurry OutlookIn spite of faulty predictions and instability, LCA isn't flying blind.
Sep 29, 2006 by Brian LawlerMerck Likes FoxHollowThe pharmaceutical giant signs another collaborative research agreement with the small-cap company.
Sep 29, 2006 by Brian LawlerThe Long Road Ahead for ViroPharmaFaced with the threat of generic competition, the company focuses its efforts on a new drug.
Sep 29, 2006 by Brian LawlerWhy the Big Deal About GDP?Gross domestic product gets a lot of attention, but other numbers matter, too.
Sep 29, 2006 by Brian LawlerPfizer Helps France Kick ButtsEurope approves the pharmaceutical's new drug to help smokers quit.
Sep 29, 2006 by Brian LawlerAlpharma's Painless ResultsA new addition to an already successful drug promises good results for investors.
Sep 28, 2006 by Brian LawlerExelixis' Growing Share CountThe developing biopharmaceutical company announces a share offering.
